Universiteit Leiden
The Netherlands

Safety and efficacy after immunization with Plasmodium falciparum sporozoites in the controlled human malaria infection model

Schats, R.

Citation
Schats, R. (2019, November 12). *Safety and efficacy after immunization with Plasmodium falciparum sporozoites in the controlled human malaria infection model*. Retrieved from https://hdl.handle.net/1887/80326

Version:	Publisher's Version
License:	Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden
Downloaded from:	https://hdl.handle.net/1887/80326

Note: To cite this publication please use the final published version (if applicable).

Cover Page

Universiteit Leiden

The handle http://hdl.handle.net/1887/80326 holds various files of this Leiden University dissertation.

Author: Schats, R.
Title: Safety and efficacy after immunization with Plasmodium falciparum sporozoites in the controlled human malaria infection model
Issue Date: 2019-11-12

Chad. April 2005. Visiting refugees in their tent in Forchana camp.

CHAPTER 7

Discussion

DISCUSSION

The development of a malaria vaccine is far from an easy path and should preferably fulfill several criteria before implementation in the field is acceptable. A malaria vaccine needs, firstly, to be highly efficacious and provide long term protection against a variety of strains. Secondly, this vaccine preferably should also have transmission blocking capacities and provide cross-species protection against *P. vivax*. Thirdly, this vaccine should be easy to administer with a minimum number of immunizations for optimal patient adherence.

Aside from a tremendous number of outstanding questions in current malaria vaccine research, two aspects of vaccine development remain of utter importance. Firstly, to develop a malaria vaccine that protects against a variety of *falciparum* strains. However, none of the current vaccine initiatives have proven to fully protect for years and, up to date, only very few whole parasite vaccine candidates have evaluated heterologous protection to other strains [1-3]. Secondly, progress needs to be made in further identification of immunological mechanisms and markers of sterile protection (and/or disease). Unravelling these mechanisms may enhance vaccine development.

Answers to these questions are still basically absent in current malaria vaccine research and this fundamental lack of knowledge hampers the development of an effective vaccine that could theoretically avoid 438.000 deaths and 214 million clinical cases of malaria annually.

Chloroquine Prophylaxis Sporozoites immunization is a highly efficient strategy to induce sterile protection

In malaria research there are several malaria vaccination models, one of these is the Chloroquine Prophylaxis Sporozoites (CPS) strategy. CPS has proven to effectively induce 100% homologous protection with a minimum of 3x15 mosquito bites [4], is highly reproducible (**chapter 2 and 3**), and has proven to last up to 28 months in two out of three volunteers as was shown by Controlled Human Malaria Infection (CHMI) [5]. Reducing the immunization dose from 3x15 infectious mosquito bites to 3x8 bites (**chapter 3**) or 3x5 bites (**chapter 2**) resulted in a clear dose-dependent profile.

This dose-dependent efficacy we found is remarkable given the breadth of approximately 50 to 200 sporozoites that are inoculated per mosquito bite. It is known that the inoculation dose is dependent on the duration of feeding of the mosquito in one bite session [6], and from animal models it is known that approximately half of the inoculated sporozoites remain in the skin [7]. But

how could this discordant finding between the variation of inoculated sporozoites per bite and the variation in numbers of parasites reaching the liver explain this striking dose-dependent efficacy? The most obvious reason could be that the variability in the number of inoculated sporozoites (within one batch of mosquitoes) may be smaller than postulated [8] and the percentage of parasites reaching the liver in relation to the parasites that remain in the skin is more constant than assumed.

After challenge with five infected mosquito bites and follow-up, volunteers can be grouped to either being sterilely protected to challenge, unprotected to challenge or being partially protected. The latter is characterised by a significantly prolonged pre-patent period compared to the unprotected control volunteers.

The prolonged pre-patent period in immunized subjects is most probably the result of killing of liver stage parasites and not by inhibition of the parasite multiplication during erythrocytic stages [9]. However, it is still unclear if this intrahepatic killing and subsequent reduced release of merozoites is a reflection of either (or a combination of) a reduction or a delayed development of parasites in the liver. This pre-(or intra) hepatic early killing of sporozoites by adaptive immune responses is characterized by inter-individual variation and may bias trial outcome especially when using small number of volunteers per study arm in trials [10].

Chloroquine and mefloquine equal as prophylaxis in the CPS model

Partly by unknown mechanisms [11], chloroquine (CQ) is able to kill the intra-erythrocytic parasite by blocking the transformation of haem into non-toxic haematoin crystals, resulting in the accumulation of a highly toxic haem. CQ also possesses immune-modulatory properties and is used in auto-immune diseases like rheumatoid arthritis or SLE diseases [12]. It is hypothesised that the efficient induction of sterile protection in CPS, found in **chapter 2 and 3**, might have been partially explained by these immune-modulating properties of CQ. CQ is known to enhance $CD8^+$ T cell responses by induction of cross-presentation in which malaria antigens are presented on MHC class I molecules to cytotoxic CD8 T-cells without the usual proteosomal processing and presentation in dendritic cells [13].

Due to widespread resistance of malaria parasites to CQ, other chemoprophylactic drugs need to be assessed for use in the CPS strategy. Mefloquine (MQ) is a registered chemoprophylactic drug that also acts on blood stages of *falciparum* and could in theory be used in the CPS model. In **chapter 3** we compared CQ to MQ which is not known for such immune-modulatory properties. Protective efficacy was expected to be reduced using MQ as prophylaxis. However, we were unable to demonstrate a difference in protective efficacy

between the use of CQ or MQ using an immunization dose of 3x8 mosquito bites (**chapter 3**). However, concerns about neuro-psychiatric side-effects of MQ, further fuelled by a FDA black-box warning, may limit its clinical use [14].

Several factors could have hypothetically affected the protective efficacy we found in the CPS model. Remaining drug concentrations of CQ or MQ could have aided parasite clearance in conjunction with suboptimal (protective) immune responses and may have led to a longer pre-patent period, even up to day of treatment and in this way could have resulted in misclassification of partially protected individuals into protected individuals. However, in **chapter 3**, all volunteers had remaining plasma levels of CQ (and desethyl-chloroquine) between 7–10 µg/L or MQ (no active metabolites) between 5–116 µg/L on the day before challenge (C-1). These concentrations are well below therapeutic or prophylactic plasma levels of CQ (30 µg/L) [15] or MQ (406-603 µg/L) [16, 17] and therefore could not have biased the protective efficacy we found. In addition, the highest MQ levels at C-1 were present in two control subjects, and their pre-patent periods (by thick smear) were 9,5 and 12 days, similar to pre-patent periods of historical controls (ranging between 7 and 12,3 days). In addition, none of the protected subjects had a positive qPCR during the entire challenge period of 21 days. Also parasite multiplication rates after challenge in both CQ and MQ groups were similar to earlier infection studies without malaria prophylaxis, suggesting that blood-stage parasite multiplication was not significantly inhibited [4] and therefore excludes anti-parasitic effects of remaining anti-malaria drug concentrations.

Another factor that could have biased the striking efficacy of CPS is that in current trials, volunteers are only monitored up to 21 days after challenge after which all subjects are curatively treated with antimalarials. A combination of remaining drug levels and an extremely low inoculation dose and/or liver load could theoretically have delayed the thick smear pre-patent period beyond 21 days. In one CPS trial [9] one volunteer did become qPCR positive, retrospectively analyzed on day 21 after challenge. It should therefore be taken in consideration to further extend the observation period after challenge in future trials to detect volunteers who may have an extreme late pre-patent period.

Adverse events, parasitaemia and safety of volunteers in CHMIs

During and after CPS and CHMI safety and adverse events are constantly monitored. Part of these adverse events can be clinical manifestations of (immune-) reactions to parasites. We observed a declining or even absence of parasites and adverse events after each subsequent immunization, suggesting early acquisition of sterile protection in subjects (**chapter 2 and 3**). This could be explained by increasing pre-erythrocytic killing of parasites by the immune sys-

tem leading to absence of circulating blood stage parasites. Unfortunately, the absence of parasites during immunizations was not a very sensitive or specific marker of protection. Nine out of 25 protected subjects (**chapter 2 and 3**) and one unprotected subject (**chapter 3**) did not show any positive qPCR signal during the entire immunization period, not even after the first immunization. Two factors may have contributed to the absence of parasitaemia during immunizations in the unprotected subject. Firstly, it is possible that the early primary innate immune response (Interleukin 1 and 6), responsible for killing of pre-erythrocytic stages, may lead to a liver load that is insufficient to induce an adaptive immune responses and establish a sterile immune response [18]. Secondly, aside a reduced liver load, the chemoprophylaxis also might have reduced parasitaemia during immunizations, keeping the parasitaemia below the qPCR detection limit of approximately 20-50 parasites per millilitre.

The predictive values calculated from both the studies combined, taking either a positive or a negative qPCR after the first immunization as a predictor, the positive predictive value for protection (PPV) was 39% and the negative predictive value (NPV) is 79%. Conclusively, a negative qPCR in the days after the first immunization is a poor predictor of protection after CHMI. When taking respectively the second and the third immunization as a predictor the NPV (91%, 83%) and in particular the PPV (67%, 100%) becomes more reliable.

Using qPCR instead of thick smear leads to lower parasitaemia levels at day of treatment in the CHMI model

Volunteers in CHMIs are closely monitored for safety reasons, and adverse events are recorded during the entire study. Serious adverse are rare in CHMIs but cardiac complications have occurred. Up to date, several instances of cardiac complications in CHMIs have occurred: one case of suspected acute coronary syndrome after immunization with a recombinant vaccine (PfLSA3) and subsequent treatment with arthemeter/lumefantrine [19], one case of myocardial infarction [20] and one case of myocarditis [21] . Despite intensified cardiac screening and selection of volunteers in the trials conducted afterwards, another case of myocarditis occurred recently. This myocarditis occurred in a CPS study 12 days after CHMI infection on the second day treatment [21].

Although parasite densities are already very low at initiation of treatment in CHMIs when compared to natural infections [22], parasite numbers on day of treatment can be considerably reduced further if treatment would be initiated based on qPCR detection of parasitaemia instead of thick smears. Although no causal relationship has been proven between cardiac complications and parasitaemia, a qPCR-based initiation of treatment, to further reduce parasitaemia in volunteers, was proposed to increase trial safety.

In **Chapter 5 and 6** we evaluated the advantages and disadvantages of using qPCR to initiate treatment. In **chapter 6** we calculated, in a retrospective analysis of nine trials, the reduction of the prepatent period and adverse events using different qPCR cut-offs.

Taking a positive qPCR as point in time to initiate treatment reduces the number of parasites a volunteer is exposed to by 90%, by shortening the pre-patent period and reducing the number of erythrocytic parasite multiplication cycles. Shortening of the prepatent period reduces the peak and the cumulative number of parasites during an infection and correspondingly reduces the number of adverse events in volunteers by approximately 70% because of earlier initiation of treatment compared to treatment after a positive thick smear. Using the studies in **chapter 2 and 3** as fictive test trials in **chapter 5**, the impact of qPCR-based initiation of treatment on adverse events and parasitaemia could only be evaluated up to day of treatment.

Unfortunately, it is unclear if this reduction in parasitaemia also will reduce the risk of cardiac events in CHMIs. For example, in the case of the myocardial infarction, no detectable parasitaemia was present and it raises the question whether reducing parasitaemia by using a low qPCR cut-off for initiation of treatment could effectively prevent cardiac complications in future trials. In **chapter 6** we evaluated what the most optimum cut-off for parasitaemia by qPCR should be and how frequent blood samples should be tested for optimal trial results. Using a qPCR threshold of 100 parasites per millilitre the prepatent period can theoretically be reduced by 3,5 days and, together with twice daily sampling, is the most optimal strategy to reduce costs and clinical burden for volunteers [23, 24].

Besides a clear benefit for subjects, the detection of immunological markers of disease, like for example cytokines or blood cells, may become more difficult to detect or can even missed because of limited immunological stimulation due to earlier treatment. Depending on the study objective, studies can be designed to either use thick smears or a positive qPCR for initiation of treatment.

qPCR based initiation of treatment most probably won't affect assessment of biomarkers for protection as they are per definition found in protected individuals without parasitaemia and before the pre-patent period of controls or unprotected individuals. Future trials have to confirm whether (early) qPCR-based treatment truly will enhance safety for volunteers and simultaneously does not (profoundly) hinder immunological assays by using different cut-offs for parasitaemia depending on the goal of the (immunological) study.

Heterologous protection in the CPS model

In malaria affected areas many different strains of *P. falciparum* exist. These strains are genetically diverse both in and between regions and are under constant selective pressure by the human immune system and anti-malaria drugs [25]. It is unclear to what extent this diversity in strains is immunologically relevant in malaria vaccine development as it is unknown which antigens of these strains are exactly involved for induction of full sterile (long lasting) heterologous protection [25]. The NF54 *P. falciparum* clone used in **chapter 2 and 3**, together with clones 3D7 and 7G8, have been extensively used in CHMI trials worldwide and were the only strains available for CHMI for a long time [10]. The NF135.C10 clone used in **chapter 4**, from a patient from Cambodia, is available for CHMI studies since a few years [7] and made testing of heterologous protection in our model feasible. New strains like NF166, originating from Ethiopia, were very scarcely used in CHMIs [26] before but were recently reintroduced in trials to study infectivity (Clinicaltrials.gov NCT01627951; McCall et al unpublished). Unfortunately, up to date, it is unknown which (combination of) strains should be used in malaria vaccine models to induce sufficient heterologous protection for future field application.

The reason why acquisition of natural immunity in malaria endemic areas (probably) takes years and years of repeated exposure is partly due the large variety of genetically different strains that hosts are exposed to in the field. It is hypothesised that each infection with a different strain creates its own unique immune response [27]. Repetitive small inoculation doses with (highly) antigenic different strains over time are insufficient to accomplish sufficiently high liver loads required for an adequate immune response and to generate subsequently sterile protection.

It is even hypothesised that each immunological different (sub)strain might need its own sufficient liver load to reach the threshold for sterile protection against that specific strain [27, 28].

Obviously, for a malaria vaccine to be efficacious, it is essential to cover this variety of strains present in an endemic area. Up to now, studies assessing heterologous protection after whole radiation- or chemically attenuated sporozoite vaccination are scarce [1-3]. In **chapter 4** we re-challenged volunteers previously immunized with the West-African NF54 strain, using the Cambodian NF135.C10 strain, and found a rather low heterologous protective efficacy of 15%. Several factors could have contributed to this relative low efficacy. Waning immunity over time could have resulted in lower efficacy as subjects were challenged 14 months after the last immunization. In addition, subjects previously received different and maybe suboptimal immunization doses which could have added to the relative low efficacy. Moreover, it is hypothesised that

NF135 has a higher infectivity and leads to a subsequent higher liver loads compared to NF54. This is supported by the finding that the NF135.C10 controls had an extremely short pre-patent period suggesting a higher liver load compared to NF54 controls. This is further underpinned by a higher first peak of NF135.C10 (2871 *Pf*/ml) parasitaemia compared to NF54 (456 *Pf*/ml) in previous controls [29]. This could implicate that the dose of five infectious bites with the NF135.C10 strain might equal ten or even fifteen infectious bites with NF54. Because of the small number of subjects, we could not include a NF54 control group in our re-challenge study by which we could have compared the heterologous efficacy we found with NF135.C10. Therefore, to assess the optimal dose for challenge, dose-escalating infection studies with NF135.C10 have been performed (Clinicaltrials.gov NCT02149550; Wammes et al unpublished).

It is hypothesised that for the induction of full homologous or even heterologous protective immunity a certain antigen magnitude is needed to overcome an immunological threshold. The required immunization dose could be further increased to amplify the (pluriform) antigen exposure and increase the immune response to the parasite. It is known that the malaria parasite exhibits profound immuno-evasive techniques preventing maximum exposure to the immune system. Genetic variability between individual parasites and cross-stage variability of antigen exposure during the parasite's lifecycle are important factors in the immuno-evasive techniques of parasites [28]. By increasing both the quality and quantity of antigens exposed to the immune-system (effectively the liver load), a more effective immune response could be mounted and overcome the induced immune-evasive capacity by the parasite. This in turn could lead to an increased (long lasting) heterologous efficacy or even cross-species protection against for example *P. vivax*. Currently, studies are ongoing assessing heterologous protection against three different strains after full effective CPS NF54 immunizations (Clinicaltrials.gov NCT02098590). In addition, recent work showed that 33 weeks after immunizations with 3 times $9x10^5$ irradiated P*f*SPZ (3D7 clone) i.v. injections, 5 out of 6 of these previously fully homologous protected individuals were also heterologously protected with strain 7G8, a clone of Brazilian origin [3].

And albeit with very limited evidence, it is hypothesised that vaccination efficacy found in malaria naïve volunteers could predict similar results in field settings [10] as the homologous NF54 challenge, used commonly in CHMIs, might be even too stringent compared to a 'natural challenge' in endemic areas with far less sporozoites inoculated by mosquito bites compared to the number of sporozoites in trials [30].

Field application of the whole-sporozoites model

The current most important and relevant phase 3 vaccine initiatives are whole sporozoite vaccines and the RTS,S subunit vaccine. The RTS,S vaccine has already been scheduled for field implementation although it has a known low efficacy. Despite the fact that the whole parasite model (e.g. CPS) is safe and is able to efficiently induce long-lasting homologous protection, several hurdles need to be taken before field application becomes suitable. Obviously, immunizing communities through mosquito bites lacks full applicability. Nonetheless, whole sporozoites vaccine candidates could be further optimized in several ways for field use. These whole sporozoite vaccine candidates could be further altered using irradiated (*Pf*SPZ), chemically attenuated (*Pf*SPZ-CVac) or genetically attenuated (GAP) parasites and could be either injected intravenously, intramuscularly of subcutaneously.

Recently progress has been made with intravenous injection of irradiated sporozoites (*Pf*SPZ), and is currently tested in several African countries [31, 32]. In this model infected mosquitoes are irradiated, dissected and sporozoites are harvested. These extracted sporozoites are purified and cryopreserved, and injected in humans after reconstitution. The irradiation dose needs to be carefully chosen to limit the development of these parasites during the liver stage, and to subsequently prevent breakthrough to blood stages, and simultaneously allow these live parasites to develop as long as possible in the liver stage to mount an adequate immune response in the human host.

The *Pf*SPZ-CVac method uses aseptic, purified, cryopreserved, non-irradiated P*f*SPZ injected intravenously whilst taking (for example) chloroquine as a chemo-prophylactic to prevent full erythrocytic multiplication and subsequent progress to disease of malaria. Also other chemo-prophylactic anti-malaria drugs can be used like mefloquine or for example ferroquine; a new drug still under phase IIb research. A single 800mg dose of ferroquine is able to provide for more than 8 days of erythrocytic parasite killing [33] and could be the ideal partner-drug for *Pf*SPZ-CVac to secure adequate serum drug concentrations while mass-vaccinating communities.

Although previous studies showed a relative low protective efficacy [34], recently, a study using three intravenous doses of 5.12×10^4 *Pf*SPZ, with an interval of 28 days, conferred short-term sterile homologous protection in 100% of subjects ten weeks after immunizations [35].

The reason previous studies using *Pf*SPZ-CVac were less effective is most probably due to both the quality and quantity of injected sporozoites, as well as the inoculation route that were suboptimal for sufficient numbers of viable parasites to reach the liver and mount an adequate immune stimulation needed for sterile protection. It is known that the route of inoculation is crucial for

the number of sporozoites that are able to reach the liver and the resulting parasite liver load is known to correlate with protective efficacy [36]. In the murine model it has been shown that injection of whole sporozoites by intravenous (i.v.) injection results in 2 to 50 fold higher liver loads compared to intramuscular (i.m.), subcutaneous (s.c.) or intradermal (i.d.) inoculation [36, 37]. The use of smaller volumes by multiple intradermal injections can increase the liver load further and might mimic probing and injection of saliva and sporozoites in the skin by *Anopheles* mosquitoes.

However, aside from the laborious process of extracting of these parasites from mosquitoes both in the *Pf*SPZ-CVac and in the *Pf*SPZ model, vialling and delivering cryo-preserved parasites to field settings remain a challenge. In addition, intravenous injection is far more time-consuming and risky than intramuscular or subcutaneous injection. And last but not least, only short-term homologous protection has been evaluated and no heterologous protection.

An alternative to the whole sporozoite *Pf*SPZ-CVac or *Pf*SPZ model is the use of genetically attenuated sporozoites (GAP) and this might be the most attractive option for future field application [38]. With GAP as a vaccine, a new field of research is entered, and it could be an alternative to the other whole parasite vaccines being either impractical because of the use of chemoprophylaxis during immunizations or because of using injection of large numbers of (irradiated) sporozoites [39]. Recently, intensive research in the production of genetically attenuated sporozoites has been performed [40-42] and has already proven a superior efficacy compared to irradiated *Pf*SPZ immunizations in humans [43]. However, the genetic alterations in the parasite, resulting in arrest of parasites in the liver, must be carefully chosen [44]. Essential genes for parasite survival in the liver are altered to arrest development and proliferation while still allowing exposure of antigens to the host during the liver stage. These genetic alterations leading to arrest of parasites could be either early or late during the development in the liver. Early liver arrest of parasites could be safer because of lower risk of breakthrough to blood-stages but might be inadequate to mount an immune response needed for sterile protection. Alternatively, late liver stage arrest of parasites might induce sufficient sterile protection but could implicate breakthrough to blood-stages and therefore being unsafe for vaccinees. This delicate balance between full arrest of parasites in the liver, allowing maximum antigen exposure, and acquisition of protective immunity but without breakthroughs to blood-stages, are critical for safety of vaccinees and vaccine efficacy. To improve efficacy and to enhance immune stimulation, adjuvants can be added, either separately or embedded in het parasites genome. Despite all current research, the production and implementation of a GAP vaccine, as any other candidate whole sporozoite vaccine, is still

a major challenge. A first-in-human trial of *Pf*Δp52Δp36GAP failed because of lack of safety due to break through to blood-stages [45]. Recently, trials in the mouse model show promising results with a double knockout of genes p52 and p36 (*Py*Δp52Δp36GAP) [46] or the genes Slarp and B9 (PbΔb9ΔslarpGAP) [47] and showed protective immunity without break through to blood-stages. In addition, in vitro studies using *Pf*Δb9ΔslarpGAP were able to infect humanized mice hepatocytes. Currently, *Pf*Δb9ΔslarpGAP is evaluated in humans for safety, immunogenicity and efficacy of protection (Clinical trial NCT03163121). Other revolutionary novel techniques using alterations in the genome of the parasite are attenuations in the CRISPR-CAS9 gene [48] and form a complete new field for both drug targets and well as for vaccine purposes [49] but have not been evaluated in humans yet.

Immunology in Malaria

Despite decades of research, up to date, it is still unknown what exactly contributes to natural or (artificial) sterile protection against *P. falciparum* in the human host. In the CPS model, the host immune system is exposed to all stages of the parasite, including early blood stages after which parasites are killed by the prophylactic drug. In whole sporozoite CPS vaccination, it is shown both in mice and humans, that sterile protection against *P. falciparum* is induced in the liver and is T-cell mediated [9, 50-52]. In line, challenge with i.v. asexual blood stages after CPS immunizations did not lead to protection. Instead, immunized subjects showed earlier fever and higher inflammation markers like IFNγ compared to controls and indicates a response sufficient for immune recognition but insufficient for killing of parasites [9]. Together these data suggest that protection is mediated by pre-erythrocytic immunity and next, raises the question how immunity is acquired during this clinically silent liver phase. *Plasmodium* can infect and replicate undetected in hepatocytes. In absence of clinical symptoms, presentation of parasite RNA in liver cells by the cytosolic pattern recognition receptor Melanoma differentiation-associated (Mda) protein, which acts as a Pathogen-associated Molecular Pattern (PAMP), induces Interferon (IFN) cytokines and triggers the recruitment of cytotoxic $CD8^+$ T cells for later killing [53].

CD8 T-cells play an important role in sterile protection

In the CPS model we were only able to assess the peripheral blood compartment for immunology taken as a reflection for the liver compartment. Taking the peripheral blood compartment as a proxy we found sterile pre-erythrocytic

protection to be likely mediated by cytotoxic $CD8^+$ T-cells, in conjunction with Th1 lineage effector mediators like IFNγ, IL2, TNF and other cytotoxic mediators (like Granzyme B and perforin) produced by innate and adaptive immune cells like NK-cells, $CD8^+$ and $CD4^+$ T-cells and γδ CD3+T-cells (**chapter 2 and 3**). These Th1 effector mediators have been assessed in several platforms: the murine model [54], non-human primates [55] and humans [56, 57].

Two mechanisms of $CD8^+$ T-cell mediated killing of infected liver cells are currently proposed, but mouse models show contradictory results. One method of killing is mediated by $CD8^+$ T-cells releasing perforin and granzyme B. The second method is mediated by the Fas receptor and its ligand on the activated effector T-cells (T_{eff}). However, granzyme$^{-/-}$, perforin pore protein (ppo)$^{-/-}$ and apoptosis ligand FasL/CD95L$^{-/-}$ deficient mice were fully protected after immunizations with irradiated sporozoites (either *P.yoelii* or *P.berghei*) [58]. This suggests that, in the mouse model, induction of sterile protection is indirectly mediated by a $CD8^+$ T-cell associated cytokine cascade and suggests to act independent of granzyme B. However, the mechanism of sterile protection might be dependent on the strain used, and additionally, it remains unclear if these findings can be extrapolated to humans.

The role of $CD4^+$ T cells in the CPS model remains unclear

In addition to $CD8^+$ T-cells, also $CD3^+$ γδ T-cells [59], NK-cells [58] and cytotoxic $CD4^+$ T-cells (**chapter 2 and 3**) [50] may play a role in pre-erythrocytic immunity but their exact contribution remains unclear. It is known that $CD4^+$ T-cells are needed to control blood-stage (natural) infections by IFN-γ production in assisting B-cells for antibody production [50]. In **chapter 2** we found cytotoxic CD4+ T-cells to be correlated in the induction of sterile protection and indirect killing of hepatocytes might take place via effector mediators despite hepatocytes lack MHCII receptors for antigen presentation.

B-cells in the CPS model correlate poorly with sterile protection

Aside from T-cell involvement, also B-cells and several antigens like AMA, MSP1-3, GLURP and CSP may play a role in the induction of sterile immunity in malaria. Unfortunately, levels of these antibodies appear to correlate poorly with sterile protection both in malaria naïve subjects [60] and in field trials [61], and show large intra-individual variation making clear that avidity of antibodies in general appear to be more important than the quantity of antibodies in sterile protection from malaria [62]. Recent immuno-epidemiological work showed antibodies (like AMA, MSP and GLURP) are associated with protection against clinical malaria in Malian [63, 64] and in Gabonese children [65]. Blood-stage parasites are able to alter both the number and function of B-cells in clinically

immune adults and further inhibit mounting of sterile protection [66]. This lack of number and function of B cells might be the reason of the insufficient association with sterile protection.

The role of regulatory T-cells in sterile protection

It is known that during natural infection T-cell responses are reduced [67, 68]. Studies in mice have demonstrated that after natural infection, $CD8^+$ T-cell responses against liver stage antigens were lower compared to immunization with irradiated sporozoites, even after repeated infections [69]. Also liver-stage specific T-cells in mice were reduced after infection [70]. Clearly, $CD8^+$ T-cell responses are down-regulated by blood-stages of malaria.

In natural infections, clinical immunity is slowly acquired but without effectively killing of all parasites leading to sterile immunity. Nonetheless, death by malaria can prevented by just one or two clinical infections [71]. In high endemic areas, when humans are repeatedly exposed to parasites, a delicate balance exists between: *i* controlling the infection and simultaneously acquisition of clinical protection and *ii* limiting collateral immunological damage whilst combatting parasites. This balance is partly effectuated by regulatory T cells (T_{reg}) which control the damage by down-regulating the force of the inflammatory response caused by T_{eff}.

During combat against malaria parasites, pro-inflammatory cytokines and chemokines, to a large part produced by Th1 $CD4^+$ T-cells, recruit inflammatory cells to the site of malaria infection. After recruitment, cytotoxic T-cells (CTL or Effector T cells (T_{eff})) and Natural Killer (NK) cells kill intracellular malaria parasites in the liver. However, the timing and degree of the response and the ratio between T_{reg} and T_{eff} [72] and subsequent inflammatory response, is crucial in successfully combatting malaria infections. Both pro-inflammatory (IFN-γ, TNF-α, IL-12) and anti-inflammatory/regulating (IL-10 and TGF-β) responses need to be carefully orchestrated and timed, and, unless tightly controlled, unlimited pro-inflammatory cytokine responses can lead to severe immune-pathology and eventually to death [73, 74]. Alternatively, too early activation of T_{reg} responses can induce immune-suppression by inhibiting Th1 responses and subsequently increase of parasitaemia [74]. It is known from malaria infections studies in humans that a high parasitaemia correlates with induction of T_{reg} and lower inflammatory responses [75] resulting in a persisting blood stage infection. On the contrary, data in mice regarding the role of T_{regs} in malaria infection are contradictory, depending on the mouse–parasite strain combination used, and large differences in T_{reg} immunological responses exist between murine and human model [76].

The necessity of (early) T_{eff} induction and IFN-γ production by immune cells has been repeatedly proven to be related with sterile immunity in malaria, both in the murine model [50] as in humans [56] [77], but could not be proven to correlate with protection and subsequently be used as a biomarker in our CPS model (**chapter 2**; [52]). It is hypothesised that *because of* the very low parasitaemia in CPS during immunizations, the high T_{eff} / T_{reg} ratio is able to induce sterile protection [67] and shape memory responses [78]. Alternatively, prolonged parasitaemia during blood-stages can suppress T cell responses and IFN-γ production both by vaccination and by natural exposure [79] and can inhibit acquisition of protection through the activation of T_{reg} [57, 80-82]. However, it remains unclear how regulatory T-cells exactly control pro-inflammatory and anti-inflammatory responses in vaccine-induced responses [82].

The importance of biomarkers in the malaria vaccine model

Molecular techniques like transcriptomics, metabolomics and proteomics can be of assistance in finding biomarkers in malaria by elucidating the immunological processes that form the basis of protection against malaria [83]. Simultaneously, new software and internet-based integrated analysis (e.g. Ingenuity or Cytobank) provide researchers in systems biology and systems immunology [84] powerful information to solve complex multi-dimensional cellular and molecular interactions that underlie malaria pathogenesis and protection. Already key gene-expression signatures have been found for licensed vaccines against for example yellow fever [85] and for other infectious diseases like tuberculosis [86]. Similar approaches for malaria could be of benefit. Up to date, no markers are known that unequivocally correlate with sterile protection in any malaria vaccine model.

Nonetheless, we found in **chapter 3** markers that are associated with parasite exposure. Merozoite Surface Protein 1 (MSP-1) antibodies, a marker of parasite exposure, were elevated in all unprotected volunteers but not in protected individuals and therefore can't be used a predictor of sterile protection [62]. A recent proof-of-principle study, comparing RNA-seq profiles before and after malaria infection between malaria-experienced (Malian) individuals and malaria-naïve (CHMI) individuals showed that activation of pro-inflammatory, interferon-mediated, immune responses were highest in the malaria naïve individuals and lowest in malaria-experienced individuals from Mali [87] showing a reduced inflammatory response which suggests both reduced manifestations of clinical malaria and simultaneously increased B-cell receptor signaling demonstrating build-up of adaptive immunity. Differences in acquisition of clinical protection are considered caused by an inflammatory ('pyrogenic') threshold. The absence of fever and concomitantly low activation of pro-in-

flammatory responses in the malaria-experienced individuals, and lack of sterile protection, might be caused by the co-infection of helminths down-regulating these CD8+ T-cell inflammatory responses.

The role of parasitic infections in malaria vaccination

A limitation of the CPS model or CHMIs in humans is that these trials can only perform immunological assays in the blood-compartment and this may not reflect processes in important sites like the liver or the spleen. Additionally, assessing T-cell responses and efficacy of vaccination in malaria endemic areas might even be more difficult than in malaria naïve subjects in hyper-controlled trial settings in the western hemisphere. Repeated exposure of individuals to malaria parasites leads generally to naturally acquired immunity (NAI), and the level of acquired immunity depends on the combination of the individuals' specific immune-system and the previous level of exposure to parasites [88]. A complicating factor of assessing efficacy after vaccination in a field setting might be the lack of tools to assess the degree of (immunological) magnitude of pre-existing NAI in subjects [89] and assessment of for example the influence on the level of T_{reg} induction and IFNγ production [90]. Also co-infections with other parasites like for example helminths could dampen the vaccine efficacy in vaccinees. A quarter of the world population is infected with helminths, of which most infections are in highly endemic low income countries [91]. Helminth infections are known to induce strong regulatory mechanisms for survival in its host and have proven to inhibit Th1 responses to infections [92, 93] and can reduce protection after vaccinations [94, 95].

Future

Given the tremendous suffering of communities of malaria it might seem that quick deployment of any malaria vaccine is necessary, nonetheless, several aspects might need to be taken into consideration. RTS,S is the first licensed, and soon mass scale distributed, vaccine against malaria. However, it is questionable if the deployment of this vaccine is justifiable at this moment. And although the vaccine averted clinical episodes of malaria shortly after vaccination in children, the short and long term clinical protection has been proven to be poor, and this vaccine does not significantly protect against severe malaria or malaria hospitalization as being demonstrated after a trial conducted in eleven African sites [96]. Most positively seen this vaccine will avert clinical malaria cases, and will be a try-out and form a base for future vaccines to be rolled out in endemic areas. Additionally, this vaccine could assist in reducing (clinical) malaria to-

gether with other existing tools like the use of bednets, insecticide spraying, adequate diagnosis and treatment of malaria. Given the poor immunogenicity and protection of RTS,S, implementation of this vaccine in endemic areas could have other effects. If vaccines do not fully protect, resistance can develop as a result of selection of the remaining resistant parasite population. Additionally, (partial) clinical vaccine-induced protection might reduce the existing natural clinical immunity of the population over time. This waning natural clinical immunity might lead to more severe malaria infections in former vaccinees and this could theoretically intensify the already existing malaria burden even more. In contrast, once-yearly administration of a malaria vaccine that is only effective short-term to communities living in areas with seasonal short malaria episodes might be considered being useful [97].

What needs to be done while in the meantime while Africa waits for an effective vaccine? One option is to further improve the effectiveness of the two most promising vaccine model: the whole parasite vaccines like *Pf*SPZ, *Pf*-SPZ-CVac or GAP, and the subunit vaccine RTS,S. The whole parasite vaccines could be further optimised by improving longevity, heterologous protection and applicability: the use of cryopreserved parasites in combination with an adjuvans or the further development of a genetically attenuated plasmodium (GAP) vaccine. The laborious manual harvesting of (genetically, (non) irradiated parasites used in whole sporozoite vaccines is in the process of being automated and new parasite culturing techniques may improve mass-scale applicability in the future. Additionally, new injection techniques like the use of multiple small volume intradermal inoculations [98] might overcome the impracticability of repeated intravenous injections.

The subunit vaccine RTS,S could be made more effective by adding different (cocktail) multi-stage immuno-potent antigens, development of new adjuvants or combination with other vaccines like ChAd63/MVA ME-TRAP [99, 100]. These multi-antigen, multi-stage or even cross-species subunit vaccines (NCT01883609, NCT02252640) using a combination of carefully selected (but yet unknown) antigens. These highly immunogenic antigens at different - including sexual - stages, might be the key solution in malaria vaccine development [101]. It is even possible that it may be necessary to produce a vaccine for different regions or continents each containing a different cocktail (of antigens) of strains. The current deployment of the RTS,S vaccine in Africa could be taken as a platform for further deployment of this vaccine or others.

Malaria vaccine community needs to combine knowledge and strengths

It is under debate whether the international malaria vaccine community should proceed on the current research route [102]. Even when new antigens are found, new delivery systems or cocktails of vaccines are used, without basic knowledge of the immune biology of malaria and without correlates of protection this may not work in the case of finding the first in-human anti-parasite vaccine. Maybe other directions need to be explored, given the current status of vaccine research and the availability of a field vaccine of only limited efficacy, even after decades of research. Malaria vaccine development could benefit maybe more from the use of genome-based research to find important immunogenic antigens and further explore immunological pathways that are responsible for protective immunity [103]. In addition, with the current highly heterogeneous landscape of vaccine research, studies need to be further harmonized worldwide to combine strengths and to further facilitate comparability between studies [104]. The success of malaria research lies in multi-disciplinary approach where disciplines like malariology, epidemiology, bio-informatics, immunology and clinicians bundle expertise and enable efficient research in conjunction with next-generation molecular and cellular techniques.

Despite all existing shortcomings in current malaria vaccine research, eradication of malaria using all available anti-malaria tools, including a highly efficacious vaccine [102], might be feasible in the coming decades as declared by Bill Gates in 2007 [104]. However, the availability of sufficient funds for now and for the future, both for vaccine-research as well as for further implementation of current malaria tools, remains a tremendous additional challenge.

REFERENCES

1. Hoffman SL, Goh LM, Luke TC, Schneider I, Le TP, Doolan DL, et al. Protection of humans against malaria by immunization with radiation-attenuated *Plasmodium falciparum* sporozoites. The Journal of infectious diseases. 2002;185(8):1155-64. doi: 10.1086/339409. PubMed PMID: 11930326.
2. Epstein JE, Paolino KM, Richie TL, Sedegah M, Singer A, Ruben AJ, et al. Protection against *Plasmodium falciparum* malaria by PfSPZ Vaccine. JCI Insight. 2017;2(1):e89154. doi: 10.1172/jci.insight.89154. PubMed PMID: 28097230.
3. Lyke KE, Ishizuka AS, Berry AA, Chakravarty S, DeZure A, Enama ME, et al. Attenuated PfSPZ Vaccine induces strain-transcending T cells and durable protection against heterologous controlled human malaria infection. Proceedings of the National Academy of Sciences of the United States of America. 2017;114(10):2711-6. doi: 10.1073/pnas.1615324114. PubMed PMID: 28223498; PubMed Central PMCID: PMCPMC5347610.
4. Roestenberg M, de Vlas SJ, Nieman AE, Sauerwein RW, Hermsen CC. Efficacy of preerythrocytic and blood-stage malaria vaccines can be assessed in small sporozoite challenge trials in human volunteers. The Journal of infectious diseases. 2012;206(3):319-23. doi: 10.1093/infdis/jis355. PubMed PMID: 22615322.
5. Roestenberg M, Teirlinck AC, McCall MB, Teelen K, Makamdop KN, Wiersma J, et al. Long-term protection against malaria after experimental sporozoite inoculation: an open-label follow-up study. Lancet. 2011;377(9779):1770-6. doi: 10.1016/S0140-6736(11)60360-7. PubMed PMID: 21514658.
6. Frischknecht F, Baldacci P, Martin B, Zimmer C, Thiberge S, Olivo-Marin JC, et al. Imaging movement of malaria parasites during transmission by Anopheles mosquitoes. Cellular microbiology. 2004;6(7):687-94. doi: 10.1111/j.1462-5822.2004.00395.x. PubMed PMID: 15186404.
7. Gueirard P, Tavares J, Thiberge S, Bernex F, Ishino T, Milon G, et al. Development of the malaria parasite in the skin of the mammalian host. Proceedings of the National Academy of Sciences of the United States of America. 2010;107(43):18640-5. doi: 10.1073/pnas.1009346107. PubMed PMID: 20921402; PubMed Central PMCID: PMC2972976.
8. Ponnudurai T, Lensen AH, van Gemert GJ, Bolmer MG, Meuwissen JH. Feeding behaviour and sporozoite ejection by infected Anopheles stephensi. Transactions of the Royal Society of Tropical Medicine and Hygiene. 1991;85(2):175-80. PubMed PMID: 1887464.
9. Bijker EM, Bastiaens GJ, Teirlinck AC, van Gemert GJ, Graumans W, van de Vegte-Bolmer M, et al. Protection against malaria after immunization by chloroquine prophylaxis and sporozoites is mediated by preerythrocytic immunity. Proceedings of the National Academy of Sciences of the United States of America. 2013;110(19):7862-7. doi: 10.1073/pnas.1220360110. PubMed PMID: 23599283; PubMed Central PMCID: PMC3651438.
10. Sauerwein RW, Roestenberg M, Moorthy VS. Experimental human challenge infections can accelerate clinical malaria vaccine development. Nature reviews Immunology. 2011;11(1):57-64. doi: 10.1038/nri2902. PubMed PMID: 21179119.

11. Olafson KN, Ketchum MA, Rimer JD, Vekilov PG. Mechanisms of hematin crystallization and inhibition by the antimalarial drug chloroquine. Proceedings of the National Academy of Sciences of the United States of America. 2015;112(16):4946-51. doi: 10.1073/pnas.1501023112. PubMed PMID: 25831526; PubMed Central PMCID: PMCPMC4413305.

12. Al-Bari MA. Chloroquine analogues in drug discovery: new directions of uses, mechanisms of actions and toxic manifestations from malaria to multifarious diseases. The Journal of antimicrobial chemotherapy. 2015;70(6):1608-21. doi: 10.1093/jac/dkv018. PubMed PMID: 25693996.

13. Accapezzato D, Visco V, Francavilla V, Molette C, Donato T, Paroli M, et al. Chloroquine enhances human CD8+ T cell responses against soluble antigens in vivo. The Journal of experimental medicine. 2005;202(6):817-28. doi: 10.1084/jem.20051106. PubMed PMID: 16157687; PubMed Central PMCID: PMC2212941.

14. FDA. FDA Drug Safety Communication: FDA approves label changes for antimalarial drug mefloquine hydrochloride due to risk of serious psychiatric and nerve side effects. 2013.

15. Rombo L, Bergqvist Y, Hellgren U. Chloroquine and desethylchloroquine concentrations during regular long-term malaria prophylaxis. Bulletin of the World Health Organization. 1987;65(6):879-83. PubMed PMID: 3501740; PubMed Central PMCID: PMC2491078.

16. Fryauff DJ, Owusu-Agyei S, Utz G, Baird JK, Koram KA, Binka F, et al. Mefloquine treatment for uncomplicated falciparum malaria in young children 6-24 months of age in northern Ghana. The American journal of tropical medicine and hygiene. 2007;76(2):224-31. PubMed PMID: 17297028.

17. Palmer KJ, Holliday SM, Brogden RN. Mefloquine. A review of its antimalarial activity, pharmacokinetic properties and therapeutic efficacy. Drugs. 1993;45(3):430-75. PubMed PMID: 7682911.

18. Vreden SG, van den Broek MF, Oettinger MC, Verhave JP, Meuwissen JH, Sauerwein RW. Cytokines inhibit the development of liver schizonts of the malaria parasite Plasmodium berghei in vivo. European journal of immunology. 1992;22(9):2271-5. doi: 10.1002/eji.1830220914. PubMed PMID: 1516619.

19. Nieman AE, de Mast Q, Roestenberg M, Wiersma J, Pop G, Stalenhoef A, et al. Cardiac complication after experimental human malaria infection: a case report. Malaria journal. 2009;8:277. doi: 10.1186/1475-2875-8-277. PubMed PMID: 19958549; PubMed Central PMCID: PMC2794284.

20. Verhage DF, Telgt DS, Bousema JT, Hermsen CC, van Gemert GJ, van der Meer JW, et al. Clinical outcome of experimental human malaria induced by Plasmodium falciparum-infected mosquitoes. Neth J Med. 2005;63(2):52-8. PubMed PMID: 15768480.

21. van Meer MP, Bastiaens GJ, Boulaksil M, de Mast Q, Gunasekera A, Hoffman SL, et al. Idiopathic acute myocarditis during treatment for controlled human malaria infection: a case report. Malaria journal. 2014;13:38. doi: 10.1186/1475-2875-13-38. PubMed PMID: 24479524; PubMed Central PMCID: PMC3909449.

22. Church LW, Le TP, Bryan JP, Gordon DM, Edelman R, Fries L, et al. Clinical manifestations of *Plasmodium falciparum* malaria experimentally induced by mosquito challenge. The Journal of infectious diseases. 1997;175(4):915-20. PubMed PMID: 9086149.

23. Walk J, Schats R, Langenberg MC, Reuling IJ, Teelen K, Roestenberg M, et al. Erratum to: Diagnosis and treatment based on quantitative PCR after controlled human malaria infection. Malaria journal. 2016;15(1):522. doi: 10.1186/s12936-016-1571-4. PubMed PMID: 27793149; PubMed Central PMCID: PMCPMC5084327.

24. Walk J, Schats R, Langenberg MC, Reuling IJ, Teelen K, Roestenberg M, et al. Diagnosis and treatment based on quantitative PCR after controlled human malaria infection. Malaria journal. 2016;15(1):398. doi: 10.1186/s12936-016-1434-z. PubMed PMID: 27495296; PubMed Central PMCID: PMCPMC4974752.

25. Takala SL, Plowe CV. Genetic diversity and malaria vaccine design, testing and efficacy: preventing and overcoming 'vaccine resistant malaria'. Parasite immunology. 2009;31(9):560-73. doi: 10.1111/j.1365-3024.2009.01138.x. PubMed PMID: 19691559; PubMed Central PMCID: PMC2730200.

26. Rieckmann KH, Carson PE, Beaudoin RL, Cassells JS, Sell KW. Letter: Sporozoite induced immunity in man against an Ethiopian strain of Plasmodium falciparum. Transactions of the Royal Society of Tropical Medicine and Hygiene. 1974;68(3):258-9. PubMed PMID: 4608063.

27. Mackinnon MJ, Marsh K. The selection landscape of malaria parasites. Science. 2010;328(5980):866-71. doi: 10.1126/science.1185410. PubMed PMID: 20466925.

28. Riley EM, Stewart VA. Immune mechanisms in malaria: new insights in vaccine development. Nature medicine. 2013;19(2):168-78. doi: 10.1038/nm.3083. PubMed PMID: 23389617.

29. Roestenberg M, O'Hara GA, Duncan CJ, Epstein JE, Edwards NJ, Scholzen A, et al. Comparison of clinical and parasitological data from controlled human malaria infection trials. PloS one. 2012;7(6):e38434. doi: 10.1371/journal.pone.0038434. PubMed PMID: 22701640; PubMed Central PMCID: PMC3372522.

30. Spring M, Polhemus M, Ockenhouse C. Controlled human malaria infection. The Journal of infectious diseases. 2014;209 Suppl 2:S40-5. doi: 10.1093/infdis/jiu063. PubMed PMID: 24872394.

31. Richie TL, Billingsley PF, Sim BK, James ER, Chakravarty S, Epstein JE, et al. Progress with *Plasmodium falciparum* sporozoite (PfSPZ)-based malaria vaccines. Vaccine. 2015;33(52):7452-61. doi: 10.1016/j.vaccine.2015.09.096. PubMed PMID: 26469720.

32. Sissoko MS, Healy SA, Katile A, Omaswa F, Zaidi I, Gabriel EE, et al. Safety and efficacy of PfSPZ Vaccine against *Plasmodium falciparum* via direct venous inoculation in healthy malaria-exposed adults in Mali: a randomised, double-blind phase 1 trial. The Lancet infectious diseases. 2017;17(5):498-509. doi: 10.1016/S1473-3099(17)30104-4. PubMed PMID: 28216244.

33. Saunders DL. Ferroquine Advances. The American journal of tropical medicine and hygiene. 2017;97(2):309-10. doi: 10.4269/ajtmh.17-0373. PubMed PMID: 28829727.

34. Bastiaens GJ, van Meer MP, Scholzen A, Obiero JM, Vatanshenassan M, van Grinsven T, et al. Safety, Immunogenicity, and Protective Efficacy of Intradermal Immunization with Aseptic, Purified, Cryopreserved *Plasmodium falciparum* Sporozoites in Volunteers Under Chloroquine Prophylaxis: A Randomized Controlled Trial. The American journal of tropical medicine and hygiene. 2016;94(3):663-73. doi: 10.4269/ajtmh.15-0621. PubMed PMID: 26711509; PubMed Central PMCID: PMCPMC4775905.

35. Mordmuller B, Surat G, Lagler H, Chakravarty S, Ishizuka AS, Lalremruata A, et al. Sterile protection against human malaria by chemoattenuated PfSPZ vaccine. Nature. 2017;542(7642):445-9. doi: 10.1038/nature21060. PubMed PMID: 28199305.

36. Nganou-Makamdop K, Ploemen I, Behet M, Van Gemert GJ, Hermsen C, Roestenberg M, et al. Reduced Plasmodium berghei sporozoite liver load associates with low protective efficacy after intradermal immunization. Parasite immunology. 2012;34(12):562-9. doi: 10.1111/pim.12000.x. PubMed PMID: 23171040.

37. Ploemen IH, Chakravarty S, van Gemert GJ, Annoura T, Khan SM, Janse CJ, et al. Plasmodium liver load following parenteral sporozoite administration in rodents. Vaccine. 2013;31(34):3410-6. doi: 10.1016/j.vaccine.2012.09.080. PubMed PMID: 23063834.

38. Butler NS, Vaughan AM, Harty JT, Kappe SH. Whole parasite vaccination approaches for prevention of malaria infection. Trends in immunology. 2012;33(5):247-54. doi: 10.1016/j.it.2012.02.001. PubMed PMID: 22405559.

39. Seder RA, Chang LJ, Enama ME, Zephir KL, Sarwar UN, Gordon IJ, et al. Protection against malaria by intravenous immunization with a nonreplicating sporozoite vaccine. Science. 2013;341(6152):1359-65. doi: 10.1126/science.1241800. PubMed PMID: 23929949.

40. Mueller AK, Camargo N, Kaiser K, Andorfer C, Frevert U, Matuschewski K, et al. Plasmodium liver stage developmental arrest by depletion of a protein at the parasite-host interface. Proceedings of the National Academy of Sciences of the United States of America. 2005;102(8):3022-7. doi: 10.1073/pnas.0408442102. PubMed PMID: 15699336; PubMed Central PMCID: PMC548321.

41. Mueller AK, Labaied M, Kappe SH, Matuschewski K. Genetically modified Plasmodium parasites as a protective experimental malaria vaccine. Nature. 2005;433(7022):164-7. doi: 10.1038/nature03188. PubMed PMID: 15580261.

42. van Dijk MR, Douradinha B, Franke-Fayard B, Heussler V, van Dooren MW, van Schaijk B, et al. Genetically attenuated, P36p-deficient malarial sporozoites induce protective immunity and apoptosis of infected liver cells. Proceedings of the National Academy of Sciences of the United States of America. 2005;102(34):12194-9. doi: 10.1073/pnas.0500925102. PubMed PMID: 16103357; PubMed Central PMCID: PMC1189305.

43. Butler NS, Schmidt NW, Vaughan AM, Aly AS, Kappe SH, Harty JT. Superior antimalarial immunity after vaccination with late liver stage-arresting genetically attenuated parasites. Cell host & microbe. 2011;9(6):451-62. doi: 10.1016/j.chom.2011.05.008. PubMed PMID: 21669394; PubMed Central PMCID: PMC3117254.

44. Keitany GJ, Vignali M, Wang R. Live attenuated pre-erythrocytic malaria vaccines. Human vaccines & immunotherapeutics. 2014;10(10):2903-9. doi: 10.4161/21645515.2014.972764. PubMed PMID: 25483648.

45. Spring M, Murphy J, Nielsen R, Dowler M, Bennett JW, Zarling S, et al. First-in-human evaluation of genetically attenuated *Plasmodium falciparum* sporozoites administered by bite of Anopheles mosquitoes to adult volunteers. Vaccine. 2013;31(43):4975-83. doi: 10.1016/j.vaccine.2013.08.007. PubMed PMID: 24029408.

46. Labaied M, Harupa A, Dumpit RF, Coppens I, Mikolajczak SA, Kappe SH. Plasmodium yoelii sporozoites with simultaneous deletion of P52 and P36 are completely attenuated and confer sterile immunity against infection. Infection and immunity. 2007;75(8):3758-68. doi: 10.1128/IAI.00225-07. PubMed PMID: 17517871; PubMed Central PMCID: PMC1951999.

47. van Schaijk BC, Ploemen IH, Annoura T, Vos MW, Foquet L, van Gemert GJ, et al. A genetically attenuated malaria vaccine candidate based on P. falciparum b9/slarp gene-deficient sporozoites. eLife. 2014;3. doi: 10.7554/eLife.03582. PubMed PMID: 25407681; PubMed Central PMCID: PMC4273440.

48. Doerflinger M, Forsyth W, Ebert G, Pellegrini M, Herold MJ. CRISPR/Cas9-The ultimate weapon to battle infectious diseases? Cellular microbiology. 2017;19(2). doi: 10.1111/cmi.12693. PubMed PMID: 27860197.

49. Lee MC, Fidock DA. CRISPR-mediated genome editing of *Plasmodium falciparum* malaria parasites. Genome Med. 2014;6(8):63. doi: 10.1186/s13073-014-0063-9. PubMed PMID: 25473431; PubMed Central PMCID: PMCPMC4254425.

50. Belnoue E, Costa FT, Frankenberg T, Vigario AM, Voza T, Leroy N, et al. Protective T cell immunity against malaria liver stage after vaccination with live sporozoites under chloroquine treatment. Journal of immunology. 2004;172(4):2487-95. PubMed PMID: 14764721.

51. Weiss WR, Sedegah M, Beaudoin RL, Miller LH, Good MF. CD8+ T cells (cytotoxic/suppressors) are required for protection in mice immunized with malaria sporozoites. Proceedings of the National Academy of Sciences of the United States of America. 1988;85(2):573-6. PubMed PMID: 2963334; PubMed Central PMCID: PMC279593.

52. Bijker EM, Teirlinck AC, Schats R, van Gemert GJ, van de Vegte-Bolmer M, van Lieshout L, et al. Cytotoxic Markers Associate with Protection against Malaria in Human Volunteers Immunized with *Plasmodium falciparum* Sporozoites. The Journal of infectious diseases. 2014. doi: 10.1093/infdis/jiu293. PubMed PMID: 24872326.

53. Liehl P, Zuzarte-Luis V, Chan J, Zillinger T, Baptista F, Carapau D, et al. Host-cell sensors for Plasmodium activate innate immunity against liver-stage infection. Nature medicine. 2014;20(1):47-53. doi: 10.1038/nm.3424. PubMed PMID: 24362933; PubMed Central PMCID: PMC4096771.

54. Matuschewski K, Hafalla JC, Borrmann S, Friesen J. Arrested Plasmodium liver stages as experimental anti-malaria vaccines. Human vaccines. 2011;7 Suppl:16-21. PubMed PMID: 21266857.

55. Weiss WR, Jiang CG. Protective CD8+ T lymphocytes in primates immunized with malaria sporozoites. PloS one. 2012;7(2):e31247. doi: 10.1371/journal.pone.0031247. PubMed PMID: 22355349; PubMed Central PMCID: PMC3280278.

56. Roestenberg M, McCall M, Hopman J, Wiersma J, Luty AJ, van Gemert GJ, et al. Protection against a malaria challenge by sporozoite inoculation. The New England journal of medicine. 2009;361(5):468-77. doi: 10.1056/NEJMoa0805832. PubMed PMID: 19641203.

57. Tsuji M. A retrospective evaluation of the role of T cells in the development of malaria vaccine. Experimental parasitology. 2010;126(3):421-5. doi: 10.1016/j.exppara.2009.11.009. PubMed PMID: 19944099; PubMed Central PMCID: PMC3603350.

58. Doolan DL, Hoffman SL. The complexity of protective immunity against liver-stage malaria. Journal of immunology. 2000;165(3):1453-62. PubMed PMID: 10903750.

59. Li C, Mannoor K, Inafuku M, Taniguchi T, Inamine Y, Miyazaki T, et al. Protective function of an unconventional gammadelta T cell subset against malaria infection in apoptosis inhibitor deficient mice. Cell Immunol. 2012;279(2):151-9. doi: 10.1016/j.cellimm.2012.09.012. PubMed PMID: 23246676.

60. Kester KE, Cummings JF, Ofori-Anyinam O, Ockenhouse CF, Krzych U, Moris P, et al. Randomized, double-blind, phase 2a trial of falciparum malaria vaccines RTS,S/AS01B and RTS,S/AS02A in malaria-naive adults: safety, efficacy, and immunologic associates of protection. The Journal of infectious diseases. 2009;200(3):337-46. doi: 10.1086/600120. PubMed PMID: 19569965.

61. Agnandji ST, Lell B, Soulanoudjingar SS, Fernandes JF, Abossolo BP, Conzelmann C, et al. First results of phase 3 trial of RTS,S/AS01 malaria vaccine in African children. The New England journal of medicine. 2011;365(20):1863-75. doi: 10.1056/NEJMoa1102287. PubMed PMID: 22007715.

62. Nahrendorf W, Scholzen A, Bijker EM, Teirlinck AC, Bastiaens GJ, Schats R, et al. Memory B-cell and antibody responses induced by *Plasmodium falciparum* sporozoite immunization. The Journal of infectious diseases. 2014;210(12):1981-90. doi: 10.1093/infdis/jiu354. PubMed PMID: 24970846; PubMed Central PMCID: PMC4241945.

63. Daou M, Kouriba B, Ouedraogo N, Diarra I, Arama C, Keita Y, et al. Protection of Malian children from clinical malaria is associated with recognition of multiple antigens. Malaria journal. 2015;14(1):56. doi: 10.1186/s12936-015-0567-9. PubMed PMID: 25653026; PubMed Central PMCID: PMC4332451.

64. Kana IH, Adu B, Tiendrebeogo RW, Singh SK, Dodoo D, Theisen M. Naturally Acquired Antibodies Target the Glutamate-Rich Protein on Intact Merozoites and Predict Protection Against Febrile Malaria. The Journal of infectious diseases. 2017;215(4):623-30. doi: 10.1093/infdis/jiw617. PubMed PMID: 28329101.

65. Muellenbeck MF, Ueberheide B, Amulic B, Epp A, Fenyo D, Busse CE, et al. Atypical and classical memory B cells produce *Plasmodium falciparum* neutralizing antibodies. The Journal of experimental medicine. 2013;210(2):389-99. doi: 10.1084/jem.20121970. PubMed PMID: 23319701; PubMed Central PMCID: PMC3570107.

66. Scholzen A, Sauerwein RW. How malaria modulates memory: activation and dysregulation of B cells in Plasmodium infection. Trends in parasitology. 2013;29(5):252-62. doi: 10.1016/j.pt.2013.03.002. PubMed PMID: 23562778.

67. Hviid L, Theander TG, Abu-Zeid YA, Abdulhadi NH, Jakobsen PH, Saeed BO, et al. Loss of cellular immune reactivity during acute *Plasmodium falciparum* malaria. FEMS microbiology immunology. 1991;3(4):219-27. PubMed PMID: 1931134.

68. Brasseur P, Agrapart M, Ballet JJ, Druilhe P, Warrell MJ, Tharavanij S. Impaired cell-mediated immunity in Plasmodium falciparum-infected patients with high-parasitemia and cerebral malaria. Clin Immunol Immunopathol. 1983;27(1):38-50. PubMed PMID: 6347486.

69. Plebanski M, Aidoo M, Whittle HC, Hill AV. Precursor frequency analysis of cytotoxic T lymphocytes to pre-erythrocytic antigens of *Plasmodium falciparum* in West Africa. Journal of immunology. 1997;158(6):2849-55. PubMed PMID: 9058821.

70. Ocana-Morgner C, Mota MM, Rodriguez A. Malaria blood stage suppression of liver stage immunity by dendritic cells. The Journal of experimental medicine. 2003;197(2):143-51. PubMed PMID: 12538654; PubMed Central PMCID: PMC2193811.

71. Gupta S, Snow RW, Donnelly CA, Marsh K, Newbold C. Immunity to non-cerebral severe malaria is acquired after one or two infections. Nature medicine. 1999;5(3):340-3. doi: 10.1038/6560. PubMed PMID: 10086393.

72. Minigo G, Woodberry T, Piera KA, Salwati E, Tjitra E, Kenangalem E, et al. Parasite-dependent expansion of TNF receptor II-positive regulatory T cells with enhanced suppressive activity in adults with severe malaria. PLoS pathogens. 2009;5(4):e1000402. doi: 10.1371/journal.ppat.1000402. PubMed PMID: 19390618; PubMed Central PMCID: PMC2668192.

73. Schofield L. Intravascular infiltrates and organ-specific inflammation in malaria pathogenesis. Immunol Cell Biol. 2007;85(2):130-7. doi: 10.1038/sj.icb.7100040. PubMed PMID: 17344907.

74. Schofield L, Grau GE. Immunological processes in malaria pathogenesis. Nature reviews Immunology. 2005;5(9):722-35. doi: 10.1038/nri1686. PubMed PMID: 16138104.

75. Walther M, Tongren JE, Andrews L, Korbel D, King E, Fletcher H, et al. Upregulation of TGF-beta, FOXP3, and CD4+CD25+ regulatory T cells correlates with more rapid parasite growth in human malaria infection. Immunity. 2005;23(3):287-96. doi: 10.1016/j.immuni.2005.08.006. PubMed PMID: 16169501.

76. Shevach EM. Mechanisms of foxp3+ T regulatory cell-mediated suppression. Immunity. 2009;30(5):636-45. doi: 10.1016/j.immuni.2009.04.010. PubMed PMID: 19464986.

77. McCall MB, Roestenberg M, Ploemen I, Teirlinck A, Hopman J, de Mast Q, et al. Memory-like IFN-gamma response by NK cells following malaria infection reveals the crucial role of T cells in NK cell activation by P. falciparum. European journal of immunology. 2010;40(12):3472-7. doi: 10.1002/eji.201040587. PubMed PMID: 21072880.

78. Todryk SM, Walther M, Bejon P, Hutchings C, Thompson FM, Urban BC, et al. Multiple functions of human T cells generated by experimental malaria challenge. European journal of immunology. 2009;39(11):3042-51. doi: 10.1002/eji.200939434. PubMed PMID: 19658096.

79. Bejon P, Mwacharo J, Kai O, Todryk S, Keating S, Lowe B, et al. The induction and persistence of T cell IFN-gamma responses after vaccination or natural exposure is suppressed by Plasmodium falciparum. Journal of immunology. 2007;179(6):4193-201. PubMed PMID: 17785859; PubMed Central PMCID: PMC2658805.

80. Mills KH. Regulatory T cells: friend or foe in immunity to infection? Nature reviews Immunology. 2004;4(11):841-55. doi: 10.1038/nri1485. PubMed PMID: 15516964.

81. Scholzen A, Minigo G, Plebanski M. Heroes or villains? T regulatory cells in malaria infection. Trends in parasitology. 2010;26(1):16-25. doi: 10.1016/j.pt.2009.10.004. PubMed PMID: 19914134.

82. Finney OC, Riley EM, Walther M. Regulatory T cells in malaria--friend or foe? Trends in immunology. 2010;31(2):63-70. doi: 10.1016/j.it.2009.12.002. PubMed PMID: 20056484.

83. Tran TM, Samal B, Kirkness E, Crompton PD. Systems immunology of human malaria. Trends in parasitology. 2012;28(6):248-57. doi: 10.1016/j.pt.2012.03.006. PubMed PMID: 22592005; PubMed Central PMCID: PMC3361535.

84. Benoist C, Germain RN, Mathis D. A plaidoyer for 'systems immunology'. Immunol Rev. 2006;210:229-34. doi: 10.1111/j.0105-2896.2006.00374.x. PubMed PMID: 16623774.

85. Gaucher D, Therrien R, Kettaf N, Angermann BR, Boucher G, Filali-Mouhim A, et al. Yellow fever vaccine induces integrated multilineage and polyfunctional immune responses. The Journal of experimental medicine. 2008;205(13):3119-31. doi: 10.1084/jem.20082292. PubMed PMID: 19047440; PubMed Central PMCID: PMC2605227.

86. Berry MP, Graham CM, McNab FW, Xu Z, Bloch SA, Oni T, et al. An interferon-inducible neutrophil-driven blood transcriptional signature in human tuberculosis. Nature. 2010;466(7309):973-7. doi: 10.1038/nature09247. PubMed PMID: 20725040; PubMed Central PMCID: PMC3492754.

87. Tran TM, Jones MB, Ongoiba A, Bijker EM, Schats R, Venepally P, et al. Transcriptomic evidence for modulation of host inflammatory responses during febrile *Plasmodium falciparum* malaria. Sci Rep. 2016;6:31291. doi: 10.1038/srep31291. PubMed PMID: 27506615; PubMed Central PMCID: PMCPMC4978957.

88. Langhorne J, Ndungu FM, Sponaas AM, Marsh K. Immunity to malaria: more questions than answers. Nature immunology. 2008;9(7):725-32. doi: 10.1038/ni.f.205. PubMed PMID: 18563083.

89. Sheehy SH, Douglas AD, Draper SJ. Challenges of assessing the clinical efficacy of asexual blood-stage *Plasmodium falciparum* malaria vaccines. Human vaccines & immunotherapeutics. 2013;9(9):1831-40. doi: 10.4161/hv.25383. PubMed PMID: 23778312; PubMed Central PMCID: PMC3906345.

90. Obiero JM, Shekalaghe S, Hermsen CC, Mpina M, Bijker EM, Roestenberg M, et al. Impact of malaria preexposure on antiparasite cellular and humoral immune responses after controlled human malaria infection. Infection and immunity. 2015;83(5):2185-96. doi: 10.1128/IAI.03069-14. PubMed PMID: 25776749; PubMed Central PMCID: PMC4399069.

91. Hotez PJ, Kamath A. Neglected tropical diseases in sub-saharan Africa: review of their prevalence, distribution, and disease burden. PLoS neglected tropical diseases. 2009;3(8):e412. doi: 10.1371/journal.pntd.0000412. PubMed PMID: 19707588; PubMed Central PMCID: PMC2727001.

92. Page KR, Scott AL, Manabe YC. The expanding realm of heterologous immunity: friend or foe? Cellular microbiology. 2006;8(2):185-96. doi: 10.1111/j.1462-5822.2005.00653.x. PubMed PMID: 16441430.

93. Finlay CM, Walsh KP, Mills KH. Induction of regulatory cells by helminth parasites: exploitation for the treatment of inflammatory diseases. Immunol Rev. 2014;259(1):206-30. doi: 10.1111/imr.12164. PubMed PMID: 24712468.

94. Brady MT, O'Neill SM, Dalton JP, Mills KH. Fasciola hepatica suppresses a protective Th1 response against Bordetella pertussis. Infection and immunity. 1999;67(10):5372-8. PubMed PMID: 10496919; PubMed Central PMCID: PMC96894.

95. Maizels RM, Pearce EJ, Artis D, Yazdanbakhsh M, Wynn TA. Regulation of pathogenesis and immunity in helminth infections. The Journal of experimental medicine. 2009;206(10):2059-66. doi: 10.1084/jem.20091903. PubMed PMID: 19770272; PubMed Central PMCID: PMC2757871.

96. Rts SCTP. Efficacy and safety of the RTS,S/AS01 malaria vaccine during 18 months after vaccination: a phase 3 randomized, controlled trial in children and young infants at 11 African sites. PLoS medicine. 2014;11(7):e1001685. doi: 10.1371/journal.pmed.1001685. PubMed PMID: 25072396; PubMed Central PMCID: PMC4114488.

97. Greenwood B, Dicko A, Sagara I, Zongo I, Tinto H, Cairns M, et al. Seasonal vaccination against malaria: a potential use for an imperfect malaria vaccine. Malaria journal. 2017;16(1):182. doi: 10.1186/s12936-017-1841-9. PubMed PMID: 28464937; PubMed Central PMCID: PMCPMC5414195.

98. Lyke KE, Laurens MB, Strauss K, Adams M, Billingsley PF, James E, et al. Optimizing Intradermal Administration of Cryopreserved *Plasmodium falciparum* Sporozoites in Controlled Human Malaria Infection. The American journal of tropical medicine and hygiene. 2015;93(6):1274-84. doi: 10.4269/ajtmh.15-0341. PubMed PMID: 26416102; PubMed Central PMCID: PMCPMC4674246.

99. Ndungu FM, Mwacharo J, Kimani D, Kai O, Moris P, Jongert E, et al. A statistical interaction between circumsporozoite protein-specific T cell and antibody responses and risk of clinical malaria episodes following vaccination with RTS,S/AS01E. PloS one. 2012;7(12):e52870. doi: 10.1371/journal.pone.0052870. PubMed PMID: 23300801; PubMed Central PMCID: PMC3531328.

100. Kimani D, Jagne YJ, Cox M, Kimani E, Bliss CM, Gitau E, et al. Translating the immunogenicity of prime-boost immunization with ChAd63 and MVA ME-TRAP from malaria naive to malaria-endemic populations. Mol Ther. 2014;22(11):1992-2003. doi: 10.1038/mt.2014.109. PubMed PMID: 24930599; PubMed Central PMCID: PMC4188556.

101. Halbroth BR, Draper SJ. Recent developments in malaria vaccinology. Adv Parasitol. 2015;88:1-49. doi: 10.1016/bs.apar.2015.03.001. PubMed PMID: 25911364.

102. Proietti C, Doolan DL. The case for a rational genome-based vaccine against malaria. Front Microbiol. 2014;5:741. doi: 10.3389/fmicb.2014.00741. PubMed PMID: 25657640; PubMed Central PMCID: PMCPMC4302942.

103. Doolan DL, Apte SH, Proietti C. Genome-based vaccine design: the promise for malaria and other infectious diseases. International journal for parasitology. 2014;44(12):901-13. doi: 10.1016/j.ijpara.2014.07.010. PubMed PMID: 25196370.

104. Roberts L, Enserink M. Malaria. Did they really say ... eradication? Science. 2007;318(5856):1544-5. doi: 10.1126/science.318.5856.1544. PubMed PMID: 18063766.